Premium
Dapagliflozin: first SGLT2 inhibitor for type 2 diabetes
Author(s) -
Chaplin Steve,
Wilding John
Publication year - 2013
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1076
Subject(s) - dapagliflozin , medicine , type 2 diabetes , diabetes mellitus , adverse effect , intensive care medicine , pharmacology , endocrinology
Dapagliflozin (Forxiga) is the first SGLT2 inhibitor licensed for the treatment of type 2 diabetes. In our New products review, Steve Chaplin presents the clinical data relating to its efficacy and adverse events, and Professor John Wilding discusses its potential role in treatment.